Aduhelm FDA-approval based on misinterpreted amyloid scans

Poul Flemming Høilund‐Carlsen; Abass Alavi; George Perry; Jorge R. Barrio

Related publications

Article2019

Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies

Aviv Ladanie, Benjamin Speich, Matthias Briel, Francesco Sclafani, Heiner C. Bucher, Arnav Agarwal, John P A Ioannidis, Tiago Pereira, Benjamin Kasenda, Lars G. Hemkens

Article2006

FDA and CPMP Rulings on Subgroup Analyses

Aldo Maggioni, Bernadette Darné, Dan Atar, Éric Abadie, Bertram Pitt, Faı̈ez Zannad

Article2023

Exploring a new pathway for biomarker-based approval of immunotherapies

Josep M. Llovet

Nature Reviews Clinical Oncology

Article2020

Generating comparative evidence on new drugs and devices after approval

Andrea Cipriani, John P A Ioannidis, Peter M. Rothwell, Paul Glasziou, Tianjing Li, Adrian F. Hernandez, Anneka Tomlinson, John Simes, Huseyin Naci

Article2014

Structure-Based Design of Functional Amyloid Materials

Wenyuan Wang, Omar M Yaghi, Cong Liu, David Eisenberg, Dan Li, Eric M. Jones, M.R. Sawaya, Hiroyasu Furukawa, Fang Luo, Magdalena I. Ivanova, Stuart A. Sievers